Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$21.79 - $32.15 $299,895 - $442,480
13,763 New
13,763 $398,000
Q3 2023

Nov 08, 2023

BUY
$16.68 - $23.66 $600,796 - $852,209
36,019 Added 175.21%
56,577 $943,000
Q2 2023

Aug 11, 2023

BUY
$18.02 - $29.36 $370,455 - $603,582
20,558 New
20,558 $567,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Campbell & CO Investment Adviser LLC Portfolio

Follow Campbell & CO Investment Adviser LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

News

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.